Lung cancer and its operable brain metastasis

Survival rate and staging problems

József Furák, Imre Troján, Tamás Szöke, László Agócs, Attila Csekeö, Jözsef Kas, Egon Svastics, József Eller, L. Tiszlavicz

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied. Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 02 months, 35 months, 611 months, 1223 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms. The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 02 months = 22% and disease-free interval 24 months and beyond = 23%. The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05). The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.

Original languageEnglish
Pages (from-to)241-247
Number of pages7
JournalAnnals of Thoracic Surgery
Volume79
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Lung Neoplasms
Survival Rate
Neoplasm Metastasis
Brain
Metastasectomy
Lung
Brain Neoplasms

Keywords

  • 10

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Lung cancer and its operable brain metastasis : Survival rate and staging problems. / Furák, József; Troján, Imre; Szöke, Tamás; Agócs, László; Csekeö, Attila; Kas, Jözsef; Svastics, Egon; Eller, József; Tiszlavicz, L.

In: Annals of Thoracic Surgery, Vol. 79, No. 1, 01.2005, p. 241-247.

Research output: Contribution to journalArticle

Furák, J, Troján, I, Szöke, T, Agócs, L, Csekeö, A, Kas, J, Svastics, E, Eller, J & Tiszlavicz, L 2005, 'Lung cancer and its operable brain metastasis: Survival rate and staging problems', Annals of Thoracic Surgery, vol. 79, no. 1, pp. 241-247. https://doi.org/10.1016/j.athoracsur.2004.06.051
Furák, József ; Troján, Imre ; Szöke, Tamás ; Agócs, László ; Csekeö, Attila ; Kas, Jözsef ; Svastics, Egon ; Eller, József ; Tiszlavicz, L. / Lung cancer and its operable brain metastasis : Survival rate and staging problems. In: Annals of Thoracic Surgery. 2005 ; Vol. 79, No. 1. pp. 241-247.
@article{afc5ef5d01c84db88da85e358be02e0c,
title = "Lung cancer and its operable brain metastasis: Survival rate and staging problems",
abstract = "We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied. Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 02 months, 35 months, 611 months, 1223 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms. The 5-year survival rates were as follows: stage I = 22{\%}, stage II = 20{\%}, stage IIIA = 22{\%}, stage IIIB = 0{\%}, and stage IV = 23{\%} after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 02 months = 22{\%} and disease-free interval 24 months and beyond = 23{\%}. The 5-year survival rate after metastasectomy was significantly greater (26{\%} vs 5{\%}) in patients without lung cancer related symptoms (p = 0.05). The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23{\%}). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.",
keywords = "10",
author = "J{\'o}zsef Fur{\'a}k and Imre Troj{\'a}n and Tam{\'a}s Sz{\"o}ke and L{\'a}szl{\'o} Ag{\'o}cs and Attila Cseke{\"o} and J{\"o}zsef Kas and Egon Svastics and J{\'o}zsef Eller and L. Tiszlavicz",
year = "2005",
month = "1",
doi = "10.1016/j.athoracsur.2004.06.051",
language = "English",
volume = "79",
pages = "241--247",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Lung cancer and its operable brain metastasis

T2 - Survival rate and staging problems

AU - Furák, József

AU - Troján, Imre

AU - Szöke, Tamás

AU - Agócs, László

AU - Csekeö, Attila

AU - Kas, Jözsef

AU - Svastics, Egon

AU - Eller, József

AU - Tiszlavicz, L.

PY - 2005/1

Y1 - 2005/1

N2 - We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied. Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 02 months, 35 months, 611 months, 1223 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms. The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 02 months = 22% and disease-free interval 24 months and beyond = 23%. The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05). The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.

AB - We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied. Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 02 months, 35 months, 611 months, 1223 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms. The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 02 months = 22% and disease-free interval 24 months and beyond = 23%. The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05). The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.

KW - 10

UR - http://www.scopus.com/inward/record.url?scp=11144251206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144251206&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2004.06.051

DO - 10.1016/j.athoracsur.2004.06.051

M3 - Article

VL - 79

SP - 241

EP - 247

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -